QUEST DIAGNOSTICS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139.2 USD | -1.15% |
|
+1.62% | +0.93% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 9.45B | Sales 2025 * | 9.76B | Capitalization | 15.46B |
|---|---|---|---|---|---|
| Net income 2024 * | 894M | Net income 2025 * | 962M | EV / Sales 2024 * | 2.07 x |
| Net Debt 2024 * | 4.07B | Net Debt 2025 * | 3.5B | EV / Sales 2025 * | 1.94 x |
| P/E ratio 2024 * |
17.8
x | P/E ratio 2025 * |
16.3
x | Employees | 44,000 |
| Yield 2024 * |
2.08% | Yield 2025 * |
2.14% | Free-Float | 68.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quest Diagnostics Incorporated
More recommendations
More press releases
More news
| 1 day | -1.15% | ||
| 1 week | +1.62% | ||
| Current month | +0.71% | ||
| 1 month | +8.27% | ||
| 3 months | +8.96% | ||
| 6 months | +4.02% | ||
| Current year | +0.93% |
1 week
136.00
141.73
1 month
125.42142.46
Current year
123.04143.63
1 year
119.59145.58
3 years
119.59174.16
5 years
73.02174.16
10 years
56.27174.16
| Managers | Title | Age | Since |
|---|---|---|---|
James Davis
CEO | Chief Executive Officer | 61 | 13-03-31 |
Sam Samad
DFI | Director of Finance/CFO | 54 | 22-07-10 |
Kristin Wallace
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Denise Morrison
BRD | Director/Board Member | 70 | 19-02-17 |
Timothy Ring
BRD | Director/Board Member | 66 | 11-12-06 |
Gail Wilensky
BRD | Director/Board Member | 80 | 96-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.84% | 254 M€ | +10.27% | - | |
| 2.17% | 2 M€ | +9.27% | ||
| 2.05% | 8 M€ | +4.88% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 139.2 | -1.15% | 741,080 |
| 24-05-13 | 140.8 | +1.70% | 1,116,214 |
| 24-05-10 | 138.4 | +0.19% | 569,562 |
| 24-05-09 | 138.2 | +1.48% | 588,254 |
| 24-05-08 | 136.1 | -0.58% | 612,360 |
Delayed Quote Nyse, May 14, 2024 at 04:00 pm EDT
More quotes
Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
- testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
- other (2.7%).
Calendar
2024-05-16
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
139.2
USD
Average target price
146.7
USD
Spread / Average Target
+5.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.93% | 15.46B | |
| +18.41% | 83.94B | |
| -29.08% | 70.3B | |
| +3.59% | 27.46B | |
| -7.08% | 17.8B | |
| +2.07% | 17.46B | |
| +6.78% | 13.49B | |
| +8.40% | 13.06B | |
| +68.45% | 12.96B | |
| +70.12% | 12.56B |
- Stock Market
- Equities
- DGX Stock
